Tarsus Cost Of Revenue vs Total Operating Expenses Analysis

TARS Stock

USD 50.84 1.18 2.38%

Tarsus Pharmaceuticals financial indicator trend analysis is much more than just breaking down Tarsus Pharmaceuticals prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Tarsus Pharmaceuticals is a good investment. Please check the relationship between Tarsus Pharmaceuticals Cost Of Revenue and its Total Operating Expenses accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.

Cost Of Revenue vs Total Operating Expenses

Cost Of Revenue vs Total Operating Expenses Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Tarsus Pharmaceuticals Cost Of Revenue account and Total Operating Expenses. At this time, the significance of the direction appears to have very strong relationship.

The correlation between Tarsus Pharmaceuticals' Cost Of Revenue and Total Operating Expenses is 0.8. Overlapping area represents the amount of variation of Cost Of Revenue that can explain the historical movement of Total Operating Expenses in the same time period over historical financial statements of Tarsus Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Tarsus Pharmaceuticals' Cost Of Revenue and Total Operating Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Cost Of Revenue of Tarsus Pharmaceuticals are associated (or correlated) with its Total Operating Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Operating Expenses has no effect on the direction of Cost Of Revenue i.e., Tarsus Pharmaceuticals' Cost Of Revenue and Total Operating Expenses go up and down completely randomly.

Correlation Coefficient

0.8

Relationship Direction	Positive
Relationship Strength	Strong

View All Relationships

Cost Of Revenue

Cost of Revenue is found on Tarsus Pharmaceuticals income statement and represents the costs associated with goods and services Tarsus Pharmaceuticals provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most indicators from Tarsus Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Tarsus Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tarsus Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.At this time, Tarsus Pharmaceuticals' Tax Provision is comparatively stable compared to the past year. Selling General Administrative is likely to gain to about 84.3 M in 2024, whereas Sales General And Administrative To Revenue is likely to drop 0.87 in 2024.

	2021	2022	2023	2024 (projected)
Reconciled Depreciation	312K	325K	628K	659.4K
Total Operating Expenses	67.1M	87.6M	159.0M	167.0M

Reconciled Depreciation Total Operating Expenses

Tarsus Pharmaceuticals fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets	Capital Stock	Net Working Capital	Common Stock	Property Plant Equipment
Total Assets		0.84	0.81	0.98	0.98	0.89	-0.87	-0.81	0.74	0.92	0.77	1.0	0.65	1.0	0.96	0.35	0.92	0.92	0.65	0.99	0.76	1.0	1.0	1.0	1.0	0.96
Other Current Liab	0.84		1.0	0.8	0.79	0.98	-0.82	-0.99	0.98	0.78	0.99	0.82	0.94	0.82	0.81	0.35	0.82	0.97	0.65	0.82	0.98	0.84	0.84	0.82	0.84	0.73
Total Current Liabilities	0.81	1.0		0.76	0.75	0.98	-0.81	-0.99	0.99	0.76	0.99	0.79	0.96	0.79	0.78	0.36	0.78	0.96	0.66	0.78	0.99	0.8	0.81	0.78	0.81	0.7
Total Stockholder Equity	0.98	0.8	0.76		1.0	0.85	-0.86	-0.75	0.68	0.9	0.72	0.98	0.58	0.98	0.9	0.16	0.92	0.9	0.49	1.0	0.71	0.98	0.98	0.98	0.98	0.96
Net Tangible Assets	0.98	0.79	0.75	1.0		0.84	-0.85	-0.75	0.68	0.91	0.71	0.98	0.58	0.98	0.9	0.17	0.92	0.89	0.51	1.0	0.7	0.98	0.98	0.98	0.98	0.96
Property Plant And Equipment Net	0.89	0.98	0.98	0.85	0.84		-0.91	-0.96	0.95	0.87	0.97	0.87	0.89	0.87	0.86	0.33	0.87	0.98	0.64	0.87	0.97	0.88	0.89	0.87	0.89	0.81
Net Debt	-0.87	-0.82	-0.81	-0.86	-0.85	-0.91		0.77	-0.77	-0.97	-0.82	-0.87	-0.69	-0.86	-0.87	-0.29	-0.85	-0.87	-0.56	-0.85	-0.83	-0.87	-0.87	-0.87	-0.87	-0.89
Retained Earnings	-0.81	-0.99	-0.99	-0.75	-0.75	-0.96	0.77		-0.99	-0.74	-0.98	-0.78	-0.97	-0.79	-0.78	-0.38	-0.76	-0.95	-0.68	-0.78	-0.97	-0.8	-0.81	-0.78	-0.81	-0.7
Accounts Payable	0.74	0.98	0.99	0.68	0.68	0.95	-0.77	-0.99		0.72	0.99	0.71	0.99	0.72	0.73	0.37	0.7	0.93	0.66	0.71	0.98	0.74	0.75	0.71	0.75	0.64
Cash	0.92	0.78	0.76	0.9	0.91	0.87	-0.97	-0.74	0.72		0.77	0.91	0.63	0.91	0.9	0.31	0.89	0.85	0.6	0.89	0.78	0.92	0.92	0.91	0.92	0.92
Non Current Assets Total	0.77	0.99	0.99	0.72	0.71	0.97	-0.82	-0.98	0.99	0.77		0.75	0.97	0.75	0.75	0.36	0.77	0.94	0.65	0.74	1.0	0.77	0.77	0.75	0.77	0.67
Cash And Short Term Investments	1.0	0.82	0.79	0.98	0.98	0.87	-0.87	-0.78	0.71	0.91	0.75		0.62	0.99	0.96	0.34	0.91	0.91	0.63	0.99	0.74	1.0	1.0	1.0	1.0	0.97
Net Receivables	0.65	0.94	0.96	0.58	0.58	0.89	-0.69	-0.97	0.99	0.63	0.97	0.62		0.63	0.64	0.39	0.62	0.87	0.65	0.61	0.96	0.65	0.66	0.62	0.66	0.54
Common Stock Total Equity	1.0	0.82	0.79	0.98	0.98	0.87	-0.86	-0.79	0.72	0.91	0.75	0.99	0.63		0.96	0.35	0.91	0.9	0.66	0.98	0.74	1.0	1.0	0.99	1.0	0.96
Common Stock Shares Outstanding	0.96	0.81	0.78	0.9	0.9	0.86	-0.87	-0.78	0.73	0.9	0.75	0.96	0.64	0.96		0.57	0.85	0.87	0.8	0.9	0.75	0.96	0.96	0.96	0.96	0.93
Non Current Liabilities Total	0.35	0.35	0.36	0.16	0.17	0.33	-0.29	-0.38	0.37	0.31	0.36	0.34	0.39	0.35	0.57		0.18	0.29	0.91	0.18	0.36	0.34	0.35	0.34	0.35	0.27
Other Current Assets	0.92	0.82	0.78	0.92	0.92	0.87	-0.85	-0.76	0.7	0.89	0.77	0.91	0.62	0.91	0.85	0.18		0.86	0.53	0.92	0.78	0.91	0.91	0.9	0.91	0.82
Other Stockholder Equity	0.92	0.97	0.96	0.9	0.89	0.98	-0.87	-0.95	0.93	0.85	0.94	0.91	0.87	0.9	0.87	0.29	0.86		0.61	0.91	0.93	0.92	0.92	0.91	0.92	0.85
Total Liab	0.65	0.65	0.66	0.49	0.51	0.64	-0.56	-0.68	0.66	0.6	0.65	0.63	0.65	0.66	0.8	0.91	0.53	0.61		0.52	0.65	0.65	0.66	0.63	0.66	0.55
Net Invested Capital	0.99	0.82	0.78	1.0	1.0	0.87	-0.85	-0.78	0.71	0.89	0.74	0.99	0.61	0.98	0.9	0.18	0.92	0.91	0.52		0.73	0.99	0.98	0.98	0.98	0.96
Property Plant And Equipment Gross	0.76	0.98	0.99	0.71	0.7	0.97	-0.83	-0.97	0.98	0.78	1.0	0.74	0.96	0.74	0.75	0.36	0.78	0.93	0.65	0.73		0.76	0.76	0.73	0.76	0.66
Total Current Assets	1.0	0.84	0.8	0.98	0.98	0.88	-0.87	-0.8	0.74	0.92	0.77	1.0	0.65	1.0	0.96	0.34	0.91	0.92	0.65	0.99	0.76		1.0	1.0	1.0	0.96
Capital Stock	1.0	0.84	0.81	0.98	0.98	0.89	-0.87	-0.81	0.75	0.92	0.77	1.0	0.66	1.0	0.96	0.35	0.91	0.92	0.66	0.98	0.76	1.0		1.0	1.0	0.96
Net Working Capital	1.0	0.82	0.78	0.98	0.98	0.87	-0.87	-0.78	0.71	0.91	0.75	1.0	0.62	0.99	0.96	0.34	0.9	0.91	0.63	0.98	0.73	1.0	1.0		1.0	0.97
Common Stock	1.0	0.84	0.81	0.98	0.98	0.89	-0.87	-0.81	0.75	0.92	0.77	1.0	0.66	1.0	0.96	0.35	0.91	0.92	0.66	0.98	0.76	1.0	1.0	1.0		0.96
Property Plant Equipment	0.96	0.73	0.7	0.96	0.96	0.81	-0.89	-0.7	0.64	0.92	0.67	0.97	0.54	0.96	0.93	0.27	0.82	0.85	0.55	0.96	0.66	0.96	0.96	0.97	0.96

Click cells to compare fundamentals

Tarsus Pharmaceuticals Account Relationship Matchups

Tarsus Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	58.3M	172.0M	178.9M	227.9M	265.5M	165.9M
Other Current Liab	299K	2.9M	7.3M	9.2M	18.4M	19.3M
Total Current Liabilities	819K	5.4M	11.5M	15.4M	36.9M	38.8M
Total Stockholder Equity	(6.0M)	166.0M	166.7M	192.9M	197.0M	131.1M
Net Tangible Assets	(6.0M)	166.0M	166.7M	192.9M	221.8M	114.0M
Property Plant And Equipment Net	280K	1.2M	1.8M	1.5M	3.3M	3.5M
Net Debt	(57.8M)	(167.3M)	(169.4M)	(51.5M)	(193.2M)	(183.6M)
Retained Earnings	(6.0M)	(32.8M)	(46.7M)	(108.8M)	(244.7M)	(232.4M)
Accounts Payable	456K	2.2M	2.9M	5.5M	18.1M	19.1M
Cash	58.0M	168.1M	171.3M	71.7M	224.9M	127.7M
Non Current Assets Total	286K	1.3M	3.0M	2.5M	9.4M	9.8M
Cash And Short Term Investments	58.0M	168.1M	171.8M	217.0M	227.4M	154.9M
Net Receivables	36K	20K	92K	3.6M	17.7M	18.6M
Common Stock Shares Outstanding	19.5M	20.3M	20.6M	24.6M	29.4M	21.8M
Liabilities And Stockholders Equity	58.3M	172.0M	178.9M	227.9M	265.5M	165.9M
Non Current Liabilities Total	63.5M	605K	699K	19.5M	31.6M	21.9M
Capital Lease Obligations	164K	831K	1.9M	773K	398K	743.8K
Other Current Assets	22K	2.5M	8.1M	4.8M	7.9M	4.3M
Other Stockholder Equity	27K	198.8M	213.4M	301.7M	441.6M	463.7M
Total Liab	64.3M	6.0M	12.2M	35.0M	68.5M	34.8M
Net Invested Capital	(6.0M)	166.0M	166.7M	212.3M	226.8M	140.2M
Property Plant And Equipment Gross	280K	548K	1.8M	957K	4.6M	4.9M
Total Current Assets	58.0M	170.7M	176.0M	225.4M	256.1M	162.9M
Net Working Capital	57.2M	165.3M	164.5M	209.9M	219.2M	150.0M
Property Plant Equipment	280K	1.2M	755K	957K	1.1M	711.5K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC